In the present study, we aimed to evaluate and compare the prognostic value of the S100A8/9 heterodimer, whose biomarker potentiality has been gaining prominence as of late, and CA15-3 as a more familiar cancer biomarker in breast cancer to further provide evidence for the serum-based applicability of these proposed markers. This evidence concerns the gene S100A8 and breast cancer.